Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24076955 | 0.93 | NLRP3 (0.61) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 | |
| SCHEMBL24077207 | 0.87 | NLRP3 (0.63) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 | |
| SCHEMBL24077110 | 0.84 | NLRP3 (0.63) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 | |
| SCHEMBL24077341 | 0.84 | NLRP3 (0.62) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 | |
| SCHEMBL24077280 | 0.84 | NLRP3 (0.62) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 | |
| SCHEMBL24077083 | 0.83 | NLRP3 (0.64) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 | |
| SCHEMBL24077228 | 0.82 | NLRP3 (0.62) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 | |
| SCHEMBL24077081 | 0.82 | NLRP3 (0.60) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 | |
| SCHEMBL24076364 | 0.81 | NLRP3 (0.61) | NLRP3MAPTAKR1B1TP53GPR139 | |
| SCHEMBL24076964 | 0.80 | NLRP3 (0.68) | NLRP3MAPTAKR1B1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885MAPT 1004/4885AKR1B1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.